Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 12/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 12/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20973146 | 0.86 | ATM (0.43) | ATMRIPK1DPP4DPP8DPP9 | |
| SCHEMBL20973810 | 0.86 | ATM (0.43) | ATMRIPK1DPP4DPP8DPP9 | |
| SCHEMBL527964 | 0.82 | MMP2 (0.39) | ATMDPP4DPP8DPP9 | |
| SCHEMBL75974 | 0.81 | RIPK1 (0.33) | ATMRIPK1DPP4 | |
| SCHEMBL28455113 | 0.80 | PLA2G1B (0.30) | — | |
| SCHEMBL28763852 | 0.78 | DPP4 (0.38) | DPP4DPP8DPP9FAP | |
| SCHEMBL27441852 | 0.78 | CHRM2 (0.47) | ATMDPP4DPP8DPP9PIK3CD | |
| SCHEMBL4398466 | 0.78 | LMNA (0.36) | RIPK1DPP4DPP8DPP9DPP7 | |
| SCHEMBL5569326 | 0.77 | ATM (0.36) | ATMRIPK1DPP4DPP8DPP9 | |
| SCHEMBL29163837 | 0.76 | UCHL1 (0.31) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117715892-A | Quaternary ammonium cation substituted compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-114845711-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-113164771-A | Imidazopyrazine derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-9969694-B2 | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9458151-B2 | Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20160272592-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-09-22 | — | — | US | disclosed |
| EP-2970202-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9187472-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150284378-A1 | ISOTHIAZOLE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | disclosed |
| EP-2920171-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | Merck Sharp & Dohme Corp. (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014164558-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-09 | — | — | WO | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| WO-2014075392-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20130303511-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2237779-A1 | BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND METHODS OF USE | Abbott Laboratories (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009085945-A1 | BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | JAK2, JAK1, JAK3 | ATM 652/4885RIPK1 475/4885DPP4 2042/4885 |
| US-20130303511-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | ATM 3489/4885RIPK1 2599/4885DPP4 2512/4885 |
| US-20150284378-A1 | ISOTHIAZOLE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | PIM1, PIM2, PIM3 | ATM 309/4885RIPK1 249/4885DPP4 960/4885 |
| US-20160272592-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, CNKSR1, CHUK | ATM 478/4885RIPK1 954/4885DPP4 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.